#KRAS

Experimental Pan-KRAS Inhibitor Enters Clinical Trials

First KRAS Targeted Therapy Shows Promise for Lung and Colon Cancer

New Approach Attacks ’Undruggable’ Cancers From the Outside In

Experimental Pan-KRAS Inhibitor Enters Clinical Trials

First KRAS Targeted Therapy Shows Promise for Lung and Colon Cancer

New Approach Attacks ’Undruggable’ Cancers From the Outside In

Top 10 Cancer Science Highlights of 2021

A look back at some of the most important science and treatment news Cancer Health covered this year.

Leading Efforts Against KRAS, the “Undruggable” Cancer Target

Damon Runyon Cancer Research Foundation scientists work to develop drugs for people with KRAS-driven cancers.

Most Lung Cancer Patients Who Never Smoked Have Targetable Mutations

Targeted therapies are available for eight tumor mutations, highlighting the importance of genomic testing.

First KRAS Drug Now Available

Lumakras (sotorasib) was granted accelerated approval for the treatment of advanced non-small-cell lung cancer.

First KRAS-Blocking Drug Approved for Advanced Lung Cancer

Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.

Behind the Breakthroughs

The theme of this issue is the science underlying advances in cancer care and treatment.

Sotorasib Shrinks Lung Cancer

More than 80% of lung cancer patients treated with the targeted therapy experienced remission or had stable disease.

KRAS-Blocking Drug Sotorasib Shrinks Lung Tumors

More than 80% of lung cancer patients treated with the targeted therapy experienced remission or had stable disease.

Scientists Are Working on mRNA Vaccines for HIV, Flu, Cancer and More

The technology used in COVID-19 vaccines may also be used to prevent other viral infections and to treat cancer and multiple sclerosis.

Meeting Your Match

Genomic testing can help customize treatment to target tumors.

Promising KRAS Drugs

Sotorasib and adagrasib target a specific cancer-causing mutation found in those with non-small-cell lung cancer and colorectal cancer.

KRAS Inhibitors Show Promise in Early Studies

Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.

KRAS Blocker Sotorasib Delays Lung Cancer Progression

The drug also showed promise for colorectal and other cancers, but it might work better in combination regimens.

Getting to the Bottom of Why KRAS Inhibitors Stop Working

The study helps explain how cancer cells adapt and tolerate treatment and identify combination therapies to improve outcomes in people.

Top 10 Cancer Treatment Highlights of 2019

Expanding the Net to Catch More Cancer

To take advantage of these new therapies, people must first learn whether their cancer harbors targetable mutations.

#KRAS

Experimental Pan-KRAS Inhibitor Enters Clinical Trials

First KRAS Targeted Therapy Shows Promise for Lung and Colon Cancer

New Approach Attacks ’Undruggable’ Cancers From the Outside In

Experimental Pan-KRAS Inhibitor Enters Clinical Trials

First KRAS Targeted Therapy Shows Promise for Lung and Colon Cancer

New Approach Attacks ’Undruggable’ Cancers From the Outside In

Top 10 Cancer Science Highlights of 2021

Leading Efforts Against KRAS, the “Undruggable” Cancer Target

Most Lung Cancer Patients Who Never Smoked Have Targetable Mutations

First KRAS Drug Now Available

First KRAS-Blocking Drug Approved for Advanced Lung Cancer

Behind the Breakthroughs

Sotorasib Shrinks Lung Cancer

KRAS-Blocking Drug Sotorasib Shrinks Lung Tumors

Scientists Are Working on mRNA Vaccines for HIV, Flu, Cancer and More

Meeting Your Match

Promising KRAS Drugs

KRAS Inhibitors Show Promise in Early Studies

KRAS Blocker Sotorasib Delays Lung Cancer Progression

Getting to the Bottom of Why KRAS Inhibitors Stop Working

Top 10 Cancer Treatment Highlights of 2019

Expanding the Net to Catch More Cancer

Science News

Blog: Food and Drug Administration (FDA)